Why Did the FDA Recall BIOCELL Implants?
The FDA initiated the July 2019 Allergan BIOCELL recall after its analysis of adverse event reports in the MAUDE database confirmed a dramatic over-representation of Allergan products in BIA-ALCL cases. The FDA had first warned of a possible BIA-ALCL link in January 2011, but as case counts grew through the 2010s, the Allergan-specific signal became undeniable: by mid-2019, Allergan BIOCELL implants accounted for approximately 85% of reported BIA-ALCL cases despite holding a significantly smaller share of the breast implant market. The FDA determined that BIOCELL recipients faced approximately 6 times the BIA-ALCL risk of patients with other manufacturers' products. The FDA requested a worldwide recall, and Allergan complied on July 24, 2019. The recall was the largest breast implant recall in FDA history.
France Recalled BIOCELL Implants One Year Earlier
A critical fact in the failure-to-warn litigation is that French health regulator ANSM suspended marketing authorization for Allergan BIOCELL textured implants in December 2018 — a full year before the U.S. recall. France's ANSM had independently identified the disproportionate risk from Allergan's macro-textured surface versus other manufacturers. This timeline means that Allergan had direct regulatory knowledge of the specific BIOCELL risk — not just general textured implant risk — well before the U.S. action. MDL 2921 plaintiffs cite the French recall as evidence that Allergan failed to act on actionable safety information in a timely manner, reinforcing the failure-to-warn narrative from 2018 through the July 2019 U.S. recall.
What the FDA Recommends for Patients With BIOCELL Implants
The FDA recommends that asymptomatic patients with recalled Allergan BIOCELL implants do NOT undergo prophylactic removal solely because of the recall, as the absolute risk of developing BIA-ALCL, while elevated relative to other implants, remains low in absolute terms. The FDA recommends that patients with BIOCELL implants receive routine follow-up with their plastic surgeon and promptly report any new symptoms — particularly late-onset seroma (sudden fluid accumulation), swelling, or lumps — for immediate evaluation. Any symptomatic patient should seek ultrasound-guided aspiration of the fluid and cytological testing for lymphoma cells. For purposes of legal claims, the FDA's recommendation against prophylactic removal does not prevent patients from choosing explantation after consulting with their surgeon, and recall-motivated explant surgery may still support legal claims for surgery costs.
Frequently Asked Questions
Related Pages
BIA-ALCL is not breast cancer — it is a T-cell lymphoma of the immune system that develops in the fluid or capsule surrounding Allergan BIOCELL textured implants. It is often curable when caught early, but advanced stages require chemotherapy and carry serious health consequences.
Learn moreBIA-ALCL staging — from Stage IA (confined to seroma fluid) through Stage IV (distant metastases) — is the single most important factor in determining the value of an Allergan breast implant lawsuit. Early-stage cases are curable; advanced stages require chemotherapy and carry worse prognosis and significantly higher compensation.
Learn moreBreast implant illness (BII) is a constellation of systemic symptoms — fatigue, brain fog, joint pain, hair loss — reported by implant patients. Unlike BIA-ALCL, BII is not yet a formally recognized diagnosis, but BII plaintiffs with Allergan BIOCELL implants are included in MDL 2921 litigation.
Learn moreThe Allergan Natrelle 410 Highly Cohesive Anatomically Shaped implant was the most widely used recalled product and is at the center of MDL 2921. McGhan textured implants — an earlier Allergan brand — are also covered by the July 2019 recall. If you received either product, you may have a claim.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreNo global Allergan BIOCELL settlement has been announced as of February 2026. The October 2026 bellwether trial will drive settlement negotiations. Based on comparable medical device MDLs, BIA-ALCL Stage IA cases may settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview